Posts by Mourabit Halima

Recently, Professor John P.A. Ioannidis and his team from Stanford University, in collaboration with Elsevier, have released the World's Top 2% Scientists list. This list primarily focuses on the "Career-long Impact" which measures the scientific influence throughout an academic career, as well as the "Single-year Impact" which highlights annual scientific achievements. Based on in-depth analysis of data from Scopus and utilizing six comprehensive metrics including citations (differentiating self-citations and others' citations), the H-index, and the HM factor (composite score, C-score), a total of 217,098 scientists have been selected. Among them, 10,687 scientists from mainland China have been included, accounting for 4.92%.

Lung cancer remains the most common and deadliest malignancy in China. Optimizing treatment strategies is essential for extending patient survival and improving quality of life. In the era of precision medicine, targeted therapies such as icotinib and befotertinib have provided significant breakthroughs for non-small cell lung cancer (NSCLC), demonstrating the commitment and innovation of Chinese pharmaceutical companies in the global fight against cancer.

At SABCS 2024, Nan Chen, MD, presented insights from a post-hoc analysis of TAILORx, exploring the role of anthracyclines in high genomic risk, node-negative HR+/HER2- breast cancer. The discussion focused on how Recurrence Score (RS) > 31 may influence treatment decisions and the potential impact of tumor size on chemotherapy benefits. These insights challenge prior assumptions about anthracycline use in HR+ breast cancer and highlight the need for a more personalized approach in high-risk patients.

At SABCS 2024, Dr. Judy Garber presented the latest 10-year follow-up results from the OlympiA trial, which continue to reinforce the role of adjuvant olaparib in patients with germline BRCA1/2 mutation-associated, high-risk HER2-negative breast cancer. With a median follow-up of 6.1 years (maximum 9.6 years), the trial confirms the long-term benefits of olaparib in reducing recurrence and improving survival outcomes.